Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

The etiopathogenesis of diffuse low-grade gliomas.

Darlix A, Gozé C, Rigau V, Bauchet L, Taillandier L, Duffau H.

Crit Rev Oncol Hematol. 2017 Jan;109:51-62. doi: 10.1016/j.critrevonc.2016.11.014. Epub 2016 Nov 27. Review.

PMID:
28010898
2.

Long-term outcomes after supratotal resection of diffuse low-grade gliomas: a consecutive series with 11-year follow-up.

Duffau H.

Acta Neurochir (Wien). 2016 Jan;158(1):51-8. doi: 10.1007/s00701-015-2621-3. Epub 2015 Nov 3.

PMID:
26530708
3.

Surgery of insular and paralimbic diffuse low-grade gliomas: technical considerations.

Michaud K, Duffau H.

J Neurooncol. 2016 Nov;130(2):289-298. Epub 2016 May 9. Review.

PMID:
27161250
4.

A new philosophy in surgery for diffuse low-grade glioma (DLGG): oncological and functional outcomes.

Duffau H.

Neurochirurgie. 2013 Feb;59(1):2-8. doi: 10.1016/j.neuchi.2012.11.001. Epub 2013 Feb 12. Review.

5.

Identifying clinical risk in low grade gliomas and appropriate treatment strategies, with special emphasis on the role of surgery.

Boissonneau S, Duffau H.

Expert Rev Anticancer Ther. 2017 Aug;17(8):703-716. doi: 10.1080/14737140.2017.1342537. Epub 2017 Jun 28. Review.

PMID:
28608763
6.

[Update on surgery for diffuse low-grade gliomas: brain mapping, hodotopy and neuroplasticity].

Duffau H.

Bull Acad Natl Med. 2011 Jan;195(1):37-49; discussion 49-51. French.

PMID:
22039702
7.

The "onco-functional balance" in surgery for diffuse low-grade glioma: integrating the extent of resection with quality of life.

Duffau H, Mandonnet E.

Acta Neurochir (Wien). 2013 Jun;155(6):951-7. doi: 10.1007/s00701-013-1653-9. Epub 2013 Feb 28. Review.

PMID:
23447053
8.

TERT promoter mutations contribute to IDH mutations in predicting differential responses to adjuvant therapies in WHO grade II and III diffuse gliomas.

Zhang ZY, Chan AK, Ding XJ, Qin ZY, Hong CS, Chen LC, Zhang X, Zhao FP, Wang Y, Wang Y, Zhou LF, Zhuang Z, Ng HK, Yan H, Yao Y, Mao Y.

Oncotarget. 2015 Sep 22;6(28):24871-83. doi: 10.18632/oncotarget.4549.

9.

Delayed leptomeningeal and subependymal seeding after multiple surgeries for supratentorial diffuse low-grade gliomas in adults.

Alvarez de Eulate-Beramendi S, Rigau V, Taillandier L, Duffau H.

J Neurosurg. 2014 Apr;120(4):833-9. doi: 10.3171/2013.10.JNS131512. Epub 2013 Nov 29.

PMID:
24286144
10.

Distinct IDH1/IDH2 mutation profiles in purely insular versus paralimbic WHO Grade II gliomas.

Gozé C, Mansour L, Rigau V, Duffau H.

J Neurosurg. 2013 Apr;118(4):866-72. doi: 10.3171/2012.11.JNS121100. Epub 2013 Jan 18.

PMID:
23330999
11.

Awake mapping for low-grade gliomas involving the left sagittal stratum: anatomofunctional and surgical considerations.

Chan-Seng E, Moritz-Gasser S, Duffau H.

J Neurosurg. 2014 May;120(5):1069-77. doi: 10.3171/2014.1.JNS132015. Epub 2014 Jan 31.

PMID:
24484222
12.

Significance of IDH mutations varies with tumor histology, grade, and genetics in Japanese glioma patients.

Mukasa A, Takayanagi S, Saito K, Shibahara J, Tabei Y, Furuya K, Ide T, Narita Y, Nishikawa R, Ueki K, Saito N.

Cancer Sci. 2012 Mar;103(3):587-92. doi: 10.1111/j.1349-7006.2011.02175.x. Epub 2012 Jan 13.

13.

The molecular biology of WHO grade II gliomas.

Marko NF, Weil RJ.

Neurosurg Focus. 2013 Feb;34(2):E1. doi: 10.3171/2012.12.FOCUS12283. Review.

PMID:
23373446
14.

[Occurrence and molecular pathology of low grade gliomas].

Murnyák B, Csonka T, Klekner A, Hortobágyi T.

Ideggyogy Sz. 2013 Sep 30;66(9-10):305-11. Hungarian.

PMID:
24358685
15.

[Histological and molecular classification of gliomas].

Figarella-Branger D, Colin C, Coulibaly B, Quilichini B, Maues De Paula A, Fernandez C, Bouvier C.

Rev Neurol (Paris). 2008 Jun-Jul;164(6-7):505-15. doi: 10.1016/j.neurol.2008.03.011. Epub 2008 Jun 10. Review. French.

PMID:
18565348
16.

Histologic classification of gliomas.

Perry A, Wesseling P.

Handb Clin Neurol. 2016;134:71-95. doi: 10.1016/B978-0-12-802997-8.00005-0. Review.

PMID:
26948349
17.

Association between glioma susceptibility loci and tumour pathology defines specific molecular etiologies.

Di Stefano AL, Enciso-Mora V, Marie Y, Desestret V, Labussière M, Boisselier B, Mokhtari K, Idbaih A, Hoang-Xuan K, Delattre JY, Houlston RS, Sanson M.

Neuro Oncol. 2013 May;15(5):542-7. doi: 10.1093/neuonc/nos284. Epub 2012 Nov 16.

18.

Children <1 year show an inferior outcome when treated according to the traditional LGG treatment strategy: a report from the German multicenter trial HIT-LGG 1996 for children with low grade glioma (LGG).

Mirow C, Pietsch T, Berkefeld S, Kwiecien R, Warmuth-Metz M, Falkenstein F, Diehl B, von Hornstein S, Gnekow AK.

Pediatr Blood Cancer. 2014 Mar;61(3):457-63. doi: 10.1002/pbc.24729. Epub 2013 Sep 4.

PMID:
24039013
19.

Low grade gliomas in eloquent locations - implications for surgical strategy, survival and long term quality of life.

Jakola AS, Unsgård G, Myrmel KS, Kloster R, Torp SH, Lindal S, Solheim O.

PLoS One. 2012;7(12):e51450. doi: 10.1371/journal.pone.0051450. Epub 2012 Dec 10.

20.

The etiology of low-grade gliomas: pathological and clinical considerations about radiation-induced low-grade gliomas.

D'Elia A, Tropeano MP, Maiola V, Frati A, Salvati M.

Neurol Sci. 2015 Jul;36(7):1091-5. doi: 10.1007/s10072-015-2136-y. Epub 2015 Mar 8.

PMID:
25749546

Supplemental Content

Support Center